Lupin’s US Generics Juggernaut Delivers Another Nice Quarter — But Can the Magic Last?
Lupin has delivered the goods this quarter. When a pharmaceutical company beats estimates across revenue, margins, and profit in a single quarter, investors tend to sit up. When it does so by margins wide enough to force analysts to revise their numbers upward, the question shifts from “is this good?”Continue Reading
